Jaume Pons

President and CSO

2023 - Current

President and CEO

2015 - 2023

We are a clinical stage company dedicated to developing novel biologics that are both safe and efficacious for use in combination with anticancer antibodies to help the immune system eradicate cancer. More information at: http://alxoncology.com/

President and CEO

2015 - 2023

Venbio Venture partner

2015

Pfizer SVP and Rinat CSO

2009 - 2015

CSO (Chief Scientific Officer) of Rinat (acquired by Pfizer) and reporting to Dr. Mikael Dolsten, M.D. President of Pfizer World Research and Development (WRD). I also served as SVP at Pfizer and member of the Pfizer WRD Leadership Team, served as Chief Technology Officer for Pfizer Biotherapeutics, member of Pfizer Senior Leadership Council and Pfizer South San Francisco Site Head.

VP and Rinat CSO

2008 - 2009

Chief Scientific Officer, Rinat

2007 - 2009

I am responsible for Rinat. Rinat is a scientifically independent company within a new Biotherapeutic initiative of Pfizer: The Biotherapeutics and Bioinnovation Centre (BBC). Reporting to Corey Goodman, companies in the BBC keep most of their independence while work closely with Pfizer to expand the biotherapeutics portfolio, the result is an organization that combines Biotech spirit with Pfizer’s Research, Development and Commercial capabilities.

Scientist 2

1999 - 2002

Posdoc (Kirsch lab)

1996 - 1999